Showing 1 - 10 of 440
Persistent link: https://www.econbiz.de/10011981115
Persistent link: https://www.econbiz.de/10011983981
Persistent link: https://www.econbiz.de/10012112734
Standard measures of bodyweight (overweight and obese, for example) fail to reflect technological progress over time - and in particular, recent progress disproportionately promoting longevity at higher bodyweights (and differences in access to it). This paper builds on the pioneering work of...
Persistent link: https://www.econbiz.de/10012533362
We study the association between infectious disease prevalence and income inequality. We hypothesize that random social mixing in an income-unequal society brings into contact a) susceptible and infected poor and b) the infected-poor and the susceptible-rich, raising infectious disease...
Persistent link: https://www.econbiz.de/10014247975
Persistent link: https://www.econbiz.de/10002699879
This paper examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: Minimum Efficacy Standards (MES) and a mix of Minimum Efficacy Standards and Price Controls mechanisms (MES PC). Through a...
Persistent link: https://www.econbiz.de/10013114471
This paper examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: minimum efficacy standards (MES) and a mix of minimum efficacy standards and price control mechanisms (MES+PC). Through a...
Persistent link: https://www.econbiz.de/10012768128
This paper examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: minimum efficacy standards (MES) and a mix of minimum efficacy standards and price control mechanisms (MES+PC). Through a...
Persistent link: https://www.econbiz.de/10012464081
The aim of this article is to analyze the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: Minimum Efficacy Standards (MES) and Price Controls (PC). We develop a model of adverse selection where a...
Persistent link: https://www.econbiz.de/10014212001